NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

罕見病的全球市場分析(2021-2031):按藥物、疾病、類型、年齡、最終用途、主要國家、主要公司的市場分析、從新型冠狀病毒感染(COVID-19)現況恢復的預測

Rare Diseases Market Report 2021-2031: Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), Disease, Type, Age, End-use, Leading National Market Analysis, Leading Companies, COVID-19 Recovery Scenarios

出版商 Visiongain Ltd 商品編碼 1004457
出版日期 內容資訊 英文 333 Pages
商品交期: 最快1-2個工作天內
價格
罕見病的全球市場分析(2021-2031):按藥物、疾病、類型、年齡、最終用途、主要國家、主要公司的市場分析、從新型冠狀病毒感染(COVID-19)現況恢復的預測 Rare Diseases Market Report 2021-2031: Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), Disease, Type, Age, End-use, Leading National Market Analysis, Leading Companies, COVID-19 Recovery Scenarios
出版日期: 2021年03月01日內容資訊: 英文 333 Pages
簡介

本報告分析了全球罕見病治療藥物市場,概述了疾病和產品,市場基本結構和最新情況,主要推動和抑制因素,以及市場規模的估計和預測值(截至2031年),按藥物/疾病/類型/年齡/最終用途和地區/主要國家(5 個地區/17 個國家/地區)的詳細趨勢、主要公司簡介、COVID-19 的影響和恢復等資訊。

目錄

第 1 章分析概述

第 2 章執行摘要

第 3 章行業考量

  • 促進因素
    • 增加罕見病治療藥物的審批
    • 各大公司強大的流水線產品
    • 提高健康意識
  • 抑制因素
    • 大量研發費用
  • 市場機會
    • 新興國家的需求增加
    • 加強各國政府的支持
  • 威脅
    • 研發成果不透明
    • 進入壁壘的高度
  • SWOT 分析
  • 行業分析:波特五力分析
    • 買方議價能力(低)
    • 供應商議價能力(中)
    • 替代產品威脅(低)
    • 新進入者的威脅(低)
    • 公司之間的競爭情況(高)
  • 2020年罕見病新藥獲批
  • 罕見病臨床試驗:冠狀病毒感染 (COVID-19) 的影響

第 4 章罕見病市場:按藥物分類

  • Revlimid:市場預測(2021-2031)
  • MabThera/Rituxan:市場預測(2021-2031)
  • Opdivo:市場預測(2021-2031)
  • Imbruvica:市場預測(2021-2031)
  • Sprycel:市場預測(2021-2031)
  • Tasigna:市場預測(2021-2031)
  • Copaxone:市場預測(2021-2031)
  • Rebif:市場預測(2021-2031)
  • Gleevec:市場預測(2021-2031)
  • Velcade:市場預測(2021-2031)
  • 其他:市場預測(2021-2031)

第 5 章罕見病市場:按疾病分類

  • 罕見癌症:市場預測(2021-2031)
    • 市場復甦情景(V形/U形/W形/L形)
  • 罕見代謝紊亂:市場預測(2021-2031)
  • 罕見神經系統疾病:市場預測(2021-2031)
  • 罕見血液病:市場預測(2021-2031)
  • 罕見傳染病:市場預測(2021-2031)
  • 其他罕見病:市場預測(2021-2031)

第 6 章罕見病市場:按類型

  • 非生物製劑:市場預測(2021-2031)
    • 市場復甦情景(V形/U形/W形/L形)
  • 生物製劑:市場預測(2021-2031)

第 7 章罕見病市場:按年齡

  • 成人:市場預測(2021-2031)
  • 兒童:市場預測(2021-2031)

第 8 章罕見病市場:按最終用途

  • 專業藥房:市場預測(2021-2031)
  • 醫院藥房:市場預測(2021-2031)
  • 零售藥房:市場預測(2021-2031)

第 9 章全球罕見病市場:按地區和主要國家(2021-2031 年)的預測

  • 市場規模和預測:按地區(2021-2031)
  • 市場復甦情景(V形/U形/W形/L形)

第10章北美罕見病市場

  • 市場規模及其預測:按國家/地區(2021-2031)
  • 美國市場(2021-2031)
    • 市場復甦情景(V形/U形/W形/L形,2021-2031)
  • 加拿大市場(2021-2031)

第 11 章歐洲罕見病市場

  • 市場規模及其預測:按國家/地區(2021-2031)
  • 德國市場(2021-2031)
  • 英國市場(2021-2031)
  • 法國市場(2021-2031)
  • 意大利市場(2021-2031)
  • 西班牙市場(2021-2031)
  • 俄羅斯市場(2021-2031)
  • 丹麥市場(2021-2031)
  • 荷蘭市場(2021-2031)
  • 其他歐洲國家的市場(2021-2031)

第 12 章亞太罕見病市場

  • 市場規模及其預測:按國家/地區(2021-2031)
  • 日本市場(2021-2031)
  • 中國市場(2021-2031)
  • 印度市場(2021-2031)
  • 其他亞太國家的市場(2021-2031)

第 13 章拉丁美洲罕見病市場

  • 市場規模及其預測:按國家/地區(2021-2031)
  • 巴西市場(2021-2031)
  • 墨西哥市場(2021-2031)
  • 其他拉美國家市場

第 14 章中東和非洲的罕見病市場

  • 市場規模及其預測:按國家/地區(2021-2031)
  • 阿拉伯聯合酋長國 (UAE) 市場(2021-2031)
  • 南非市場(2021-2031)
  • 其他中東和非洲國家的市場(2021-2031)

第 15 章公司簡介

  • Pfizer Inc.
  • Novartis AG
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Biogen Inc.
  • Teva Pharmaceuticals
  • Alexion Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Abbive
  • Bristol Myers Squibb
  • Takeda Pharmaceuticals
  • Roche
  • Johnson & Johnson Services, Inc.

第 16 章結論和建議

目錄
Product Code: PHA1076

Title:
Rare Diseases Market Report 2021-2031
Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), by Disease (Rare Oncology Diseases, Rare Metabolic Diseases, Rare Neurologic Diseases, Rare Haematology Diseases, Rare Infectious Diseases, Other Rare Diseases), by Type (Non Biologics, Biologics), by Age (Adult, Pediatric), by End-use (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

Rare Diseases Market - Our New Study Reveals Trends, R&D Progress, and Predicted Revenues over the Next Decade

The global rare diseases market was valued at US$xx billion in 2021 and is likely to reach US$xx billion by 2026 growing at a CAGR of xx% from 2021-2026. Furthermore, the market is predicted to generate revenue of US$xx billion by 2031. Increasing cases of rare genetic diseases coupled with rising number of US FDA approvals for treatment of rare diseases is likely to promote the market growth. The growing emphasis on scientific activities and the development of new medicinal medicines has expanded the market importance of treating rare diseases.

What Are The Market Driving Factors?

  • Increasing number of approvals for rare diseases
  • Robust pipeline by major players
  • Increasing health awareness

What Are The Market Opportunities?

  • Increasing demand from emerging economies
  • Increasing government support

Some of the novel drugs approved in 2020 for rare diseases

  • Evrysdi
  • Lampit
  • Orladeyo
  • Artesunate

In addition, increasing product advances are contributing to the launch of ground-breaking technical instruments for the detection of unusual genetic disorders. In addition, supportive government initiatives aimed at increasing recognition of the treatment of rare diseases are contributing to expanded implementation of successful rare disease therapies. <>In terms of drugs, others segment dominated the global market by generating revenue of US$xx billion in 2021 and is likely to grow at a CAGR of xx% over the forecast period.

Key highlights about rare diseases market:

  • Majority of rare diseases effect new born and are diagnosed before the age of 5 years
  • Genetic testing finds major application in diagnosing variety of rare diseases
  • Rising number of new born screenings is expected to increase the diagnosis rate of rare diseases
  • Prenatal screening finds its application in diagnosing Trisomy 13, Trisomy 18 and Edward's disease

Discover how to stay ahead

Our 330+ pages report provides 400+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Rare Diseases Market. See how to exploit the opportunities.

Rare Diseases Market Segmentation

Drugs

  • Revlimid
  • MabThera/Rituxan
  • Opdivo
  • Imbruvica
  • Sprycel
  • Tasigna
  • Copaxone
  • Rebif

Disease

  • Rare Oncology Diseases
  • Rare Metabolic Diseases
  • Rare Neurologic Diseases
  • Rare Hematology Diseases
  • Rare Infectious Diseases
  • Other Rare Diseases

Type

  • Non Biologics
  • Biologics

Age

  • Adult
  • Pediatric

End use

  • Specialty Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

COVID-19 Impact Recovery Scenarios

This report includes Baseline Forecasts along with Different Rebound Scenarios to help analyze the global rare disease market-no matter how COVID-19 affects the economy.

Forecasts to 2031 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.

Leading countries and the potential for market growth

Overall world revenue for rare disease Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Rare Disease Market report helps you

In summary, our 330+ page report provides you with the following knowledge:

  • Revenue forecasts to 2031 for rare disease Market, with forecasts for disease and end use, each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2031 for 5 regional and 17 key national markets- See forecasts for the rare disease market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Also forecasted is the market in the U.S., Canada, UK, France, Germany, Italy, Spain, Russia, Denmark, Netherland, Japan, India, China, Brazil, Mexico, South Africa, and UAE among other prominent economies.
  • Prospects for established firms and those seeking to enter the market- including company profiles for 15 of the major companies involved in the rare disease Market. Some of the companies profiled in this report are Pfizer Inc., Novartis AG, Merck KGaA, F. Hoffmann-La Roche Ltd, Amgen Inc., Biogen Inc., Teva Pharmaceuticals, Alexion Pharmaceuticals, Inc., Sanofi S.A., AbbVie, Bristol Myers Squibb, Takeda Pharmaceuticals, Roche, Johnson & Johnson Services, Inc.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the rare disease market and leading companies. You will find data, trends, and predictions.

Who should read this report?

  • Senior Executives
  • Business Development Managers
  • Marketing Directors
  • Consultants
  • Chief Executive Officers
  • Governments, agencies & organizations actively working or interested in the rare disease industry will also find significant value in our research.

Buy our report today “Rare Diseases Market Report 2021-2031: Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), by Disease (Rare Oncology Diseases, Rare Metabolic Diseases, Rare Neurologic Diseases, Rare Haematology Diseases, Rare Infectious Diseases, Other Rare Diseases), by Type (Non Biologics, Biologics), by Age (Adult, Pediatric), by End-use (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios”. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Introduction to Rare Diseases Market
  • 1.2 The Orphan Drug Act
    • 1.2.1 What is the Orphan Drug Act?
    • 1.2.2 What is an orphan drug?
    • 1.2.3 How does the FDA encourage the development of medical products to diagnose and treat rare diseases?
    • 1.2.4 What does the FDA Office of Orphan Products Development do?
    • 1.2.5 How do the FDA medical product centers support rare disease product development?
  • 1.3 Types of Rare disease
  • 1.4 Why You Should Read This Report
  • 1.5 What This Report Delivers
  • 1.6 Key Questions Answered By This Analytical Report Include:
  • 1.7 Who is This Report For?
  • 1.8 Methodology
    • 1.8.1 COVID-19 Impact: Recovery Scenarios
    • 1.8.2 Market Evaluation & Forecasting Methodology
  • 1.9 Frequently Asked Questions (FAQs)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2 Executive Summary

3 Industry Insights

  • 3.1 Drivers
    • 3.1.1 Increasing number of approvals for rare diseases
    • 3.1.2 Robust pipeline by major players
    • 3.1.3 Increasing health awareness
  • 3.2 Restraints
    • 3.2.1 High R&D costs
  • 3.3 Opportunities
    • 3.3.1 Increasing demand from emerging economies
    • 3.3.2 Increasing government support
  • 3.4 Threats
    • 3.4.1 Uncertain R&D Results
    • 3.4.2 High entry barriers
  • 3.5 SWOT Analysis
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Buyers (Low)
    • 3.6.2 Bargaining Power of Suppliers (medium)
    • 3.6.3 Threat of Substitutes (Low)
    • 3.6.4 Threat of New Entrants (Low)
    • 3.6.5 Industry Rivalry (High)
  • 3.7 Novel drugs approved in 2020 for rare diseases
  • 3.8 The Impact of COVID-19 on rare disease clinical trials

4 Rare Diseases Market by Drugs

  • 4.1 Revlimid Segment Market Forecast, 2021-2031
    • 4.1.1 Rising number of new cases getting diagnosed with multiple myeloma to support growth
  • 4.2 MabThera/Rituxan Segment Market Forecast, 2021-2031
    • 4.2.1 Rheumatoid arthritis to fuel market demand
  • 4.3 Opdivo Segment Market Forecast, 2021-2031
    • 4.3.1 Combiantion drug therapy to support market demand
  • 4.4 Imbruvica Segment Market Forecast, 2021-2031
    • 4.4.1 Rising incidence of B cell cancers to boost demand
  • 4.5 Sprycel Segment Market Forecast, 2021-2031
    • 4.5.1 Improving diagnosis rate of acute lymphoblastic leukaemia to rise demand in future
  • 4.6 Avonex Segment Market Forecast, 2021-2031
    • 4.6.1 Positive advent in clinical trials for multiple disorders to fuel market growth
  • 4.7 Tasigna Segment Market Forecast, 2021-2031
    • 4.7.1 Increasing demand to overcome imatinib resistace to increase market revenue
  • 4.8 Copaxone Segment Market Forecast, 2021-2031
    • 4.8.1 Complications associated with relapsing MS to support market development
  • 4.9 Rebif Segment Market Forecast, 2021-2031
    • 4.9.1 Rising cases of relapsing MS to increase market demand
  • 4.10 Gleevec Segment Market Forecast, 2021-2031
    • 4.10.1 Increasing demand for rare cancer medication
  • 4.11 Velcade Segment Market Forecast, 2021-2031
    • 4.11.1 Generic completion to hinder market growth
  • 4.12 Others Segment Market Forecast, 2021-2031

5 Rare Diseases Market by Disease

  • 5.1 Rare Oncology Diseases Segment Market Forecast, 2021-2031
    • 5.1.1 Increasing Target Population Getting Diagnosed With Rare Cancers
    • 5.1.2 Recovery Scenarios (V, U, W, L)
  • 5.2 Rare Metabolic Diseases Segment Market Forecast, 2021-2031
    • 5.2.1 Advancements in gene therapy to fuel rare metabolic diseases segment
    • 5.2.2 Recovery Scenarios (V, U, W, L)
  • 5.3 Rare Neurologic Diseases Segment Market Forecast, 2021-2031
    • 5.3.1 Advent of genome sequencing to fuel rare neurological disease market
    • 5.3.2 Recovery Scenarios (V, U, W, L)
  • 5.4 Rare Hematology Diseases Segment Market Forecast, 2021-2031
    • 5.4.1 Increased blood-related diseases such as leukaemia, sickle cell anaemia, and myeloma continue to contribute market growth
    • 5.4.2 Recovery Scenarios (V, U, W, L)
  • 5.5 Rare Infectious Diseases Segment Market Forecast, 2021-2031
    • 5.5.1 Advanced Healthcare Infrastructure in Developed and Emerging Countries to Fuel Rare Infectious Disease Segment
    • 5.5.2 Recovery Scenarios (V, U, W, L)
  • 5.6 Other Rare Diseases Segment Market Forecast, 2021-2031
    • 5.6.1 Increasing government actions to increase awareness is likely to support market growth
    • 5.6.2 Recovery Scenarios (V, U, W, L)

6 Rare Diseases Market by Type

  • 6.1 Non Biologics Segment Market Forecast, 2021-2031
    • 6.1.1 Small molecules approvals to fuel non biologics segment
    • 6.1.2 Recovery Scenarios (V, U, W, L)
  • 6.2 Biologics Segment Market Forecast, 2021-2031
    • 6.2.1 Robust growth in number of new drug approvals to fuel biologics market
    • 6.2.2 Recovery Scenarios (V, U, W, L)

7 Rare Diseases Market by Age

  • 7.1 Adult Segment Market Forecast, 2021-2031
    • 7.1.1 Rising number of cases foe Huntington, ALS, and Cancer to boost the segment growth
    • 7.1.2 Recovery Scenarios (V, U, W, L)
  • 7.2 Pediatric Segment Market Forecast, 2021-2031
    • 7.2.1 Improving neonatal screening techniques to boost the segment growth
    • 7.2.2 Recovery Scenarios (V, U, W, L)

8 Rare Diseases Market by End Use

  • 8.1 Specialty Pharmacies Segment Market Forecast, 2021-2031
    • 8.1.1 Adequate drug availability of drugs to fuel the segment
    • 8.1.2 Recovery Scenarios (V, U, W, L)
  • 8.2 Hospital Pharmacies Segment Market Forecast, 2021-2031
    • 8.2.1 Large number of patients admitted to hospitals opt hospital pharmacies for procuring medicines
    • 8.2.2 Recovery Scenarios (V, U, W, L)
  • 8.3 Retail Pharmacies Segment Market Forecast, 2021-2031
    • 8.3.1 Growing urbanization and expansion of retail pharmacy chains to fuel the segment growth
    • 8.3.2 Recovery Scenarios (V, U, W, L)

9 Regional and Leading National Rare Diseases Market Forecasts 2021-2031

  • 9.1 Global Rare Diseases Market by Region Forecast 2021-2031
  • 9.2 Recovery Scenarios (V, U, W, L)

10 North America Rare Diseases Market

  • 10.1 Well-developed healthcare infrastructure coupled with large number of approvals to fuel the market
  • 10.2 North America Rare Diseases Market by Country, Forecast 2021-2031
  • 10.3 U.S. Rare Diseases Market Forecast, 2021-2031
    • 10.3.1 Large number of clinical trials to propel the market
    • 10.3.2 Recovery Scenarios (V, U, W, L): U.S. Rare Diseases Market Forecast, 2021-2031
  • 10.4 Canada Rare Diseases Market Forecast, 2021-2031
    • 10.4.1 Increasing number of clinical trials within the country to fuel market growth
    • 10.4.2 Recovery Scenarios (V, U, W, L): Canada Rare Diseases Market Forecast, 2021-2031

11 Europe Rare Diseases Market

  • 11.1 Highly developed medical imaging sector to increase diagnosis of rare diseases to further propel drug sales
  • 11.2 Europe Rare Diseases Market by Country, Forecast 2021-2031
  • 11.3 Germany Rare Diseases Market Forecast, 2021-2031
    • 11.3.1 Increasing community awareness to increase the market growth
    • 11.3.2 Recovery Scenarios (V, U, W, L): Spain Rare Diseases Market Forecast, 2021-2031
  • 11.4 UK Rare Diseases Market Forecast, 2021-2031
    • 11.4.1 Rare disease framework to support market growth in near future
    • 11.4.2 Recovery Scenarios (V, U, W, L): UK Rare Diseases Market Forecast, 2021-2031
  • 11.5 France Rare Diseases Market Forecast, 2021-2031
    • 11.5.1 Government support to favour the market growth
    • 11.5.2 Recovery Scenarios (V, U, W, L): France Rare Diseases Market Forecast, 2021-2031
  • 11.6 Italy Rare Diseases Market Forecast, 2021-2031
    • 11.6.1 Pharmaceutical research and funding's to propel market growth
    • 11.6.2 Recovery Scenarios (V, U, W, L): Italy Rare Diseases Market Forecast, 2021-2031
  • 11.7 Spain Rare Diseases Market Forecast, 2021-2031
    • 11.7.1 Specific pricing policy to propel the growth
    • 11.7.2 Recovery Scenarios (V, U, W, L): Spain Rare Diseases Market Forecast, 2021-2031
  • 11.8 Russia Rare Diseases Market Forecast, 2021-2031
    • 11.8.1 R&D to boost the Russian market in coming years
    • 11.8.2 Recovery Scenarios (V, U, W, L): Russia Rare Diseases Market Forecast, 2021-2031
  • 11.9 Denmark Rare Diseases Market Forecast, 2021-2031
    • 11.9.1 Rising healthcare spending to increase drug penetration which in turn to fuel the market growth
    • 11.9.2 Recovery Scenarios (V, U, W, L): Russia Rare Diseases Market Forecast, 2021-2031
  • 11.10 Netherlands Rare Diseases Market Forecast, 2021-2031
    • 11.10.1 Growing healthcare spending to fuel the demand for rare disease drugs
    • 11.10.2 Recovery Scenarios (V, U, W, L): Netherlands Rare Diseases Market Forecast, 2021-2031
  • 11.11 Rest of Europe Rare Diseases Market Forecast, 2021-2031
    • 11.11.1 Growing prevalence of rare neurological diseases to drive the market growth
    • 11.11.2 Recovery Scenarios (V, U, W, L): Rest of Europe Rare Diseases Market Forecast, 2021-2031

12 Asia Pacific Rare Diseases Market

  • 12.1 Developing healthcare infrastructure to improve diagnosis rates
  • 12.2 Asia Pacific Rare Diseases Market by Country, Forecast 2021-2031
  • 12.3 Japan Rare Diseases Market Forecast, 2021-2031
    • 12.3.1 Rising geriatric population to fuel the demand for drugs
    • 12.3.2 Recovery Scenarios (V, U, W, L): Japan Rare Diseases Market Forecast, 2021-2031
  • 12.4 China Rare Diseases Market Forecast, 2021-2031
    • 12.4.1 Largest population base to create huge potential market for rare disease drugs
    • 12.4.2 Recovery Scenarios (V, U, W, L): China Rare Diseases Market Forecast, 2021-2031
  • 12.5 India Rare Diseases Market Forecast, 2021-2031
    • 12.5.1 Rising prevalence of rare genetic diseases to propel growth in future
    • 12.5.2 Recovery Scenarios (V, U, W, L): India Rare Diseases Market Forecast, 2021-2031
  • 12.6 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031
    • 12.6.1 Progress in public awareness and investment opportunities to fuel the market growth
    • 12.6.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031

13 Latin America Rare Diseases Market

  • 13.1 Rising demand from brazil to increase regional market revenues
  • 13.2 Latin America Rare Diseases Market by Country, Forecast 2021-2031
  • 13.3 Brazil Rare Diseases Market Forecast, 2021-2031
    • 13.3.1 Increasing number of approvals for orphan drugs to propel the country market
    • 13.3.2 Recovery Scenarios (V, U, W, L): Brazil Rare Diseases Market Forecast, 2021-2031
  • 13.4 Mexico Rare Diseases Market Forecast, 2021-2031
    • 13.4.1 Transformation of current medical system predicted to improve market penetration for rare drugs
    • 13.4.2 Recovery Scenarios (V, U, W, L): Mexico Rare Diseases Market Forecast, 2021-2031
  • 13.5 Rest of Latin America Rare Diseases Market Forecast, 2021-2031
    • 13.5.1 Improving healthcare infrastructure to fuel demand for rare drugs
    • 13.5.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Rare Diseases Market Forecast, 2021-2031

14 Middle East and Africa Rare Diseases Market

  • 14.1 increasing awareness regarding rare disease to fuel market
  • 14.2 Middle East and Africa Rare Diseases Market by Country, Forecast 2021-2031
  • 14.3 UAE Rare Diseases Market Forecast, 2021-2031
    • 14.3.1 Fastrack approvals with government support to fuel market growth
    • 14.3.2 Recovery Scenarios (V, U, W, L): UAE Rare Diseases Market Forecast, 2021-2031
  • 14.4 South Africa Rare Diseases Market Forecast, 2021-2031
    • 14.4.1 Healthcare reforms are likely to increase demand for rare drugs
    • 14.4.2 Recovery Scenarios (V, U, W, L): South Africa Rare Diseases Market Forecast, 2021-2031
  • 14.5 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031
    • 14.5.1 Improving healthcare infrastructure to increase rare drug availability
    • 14.5.2 Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031

15 Company Profiles

  • 15.1 Pfizer Inc.
    • 15.1.1 Company Overview
    • 15.1.2 Products / Services
    • 15.1.3 Financials, 2015-2019 (US$ billion, AGR %)
    • 15.1.4 Mergers & Acquisitions (M&A) Activity
  • 15.2 Novartis AG
    • 15.2.1 Company Overview
    • 15.2.2 Products / Services
    • 15.2.3 Total Company Sales, 2015-2018
  • 15.3 Merck KGaA
    • 15.3.1 Company Overview
    • 15.3.2 Products / Services
    • 15.3.3 Financials, 2015-2019 (US$ billion, AGR %)
    • 15.3.4 Mergers & Acquisitions (M&A) Activity
  • 15.4 F. Hoffmann-La Roche Ltd.
    • 15.4.1 Company Overview
    • 15.4.2 Products / Services
    • 15.4.3 Financials, 2015-2019 (US$ billion, AGR %)
  • 15.5 Amgen Inc.
    • 15.5.1 Company Overview
    • 15.5.2 Products / Services
    • 15.5.3 Financials, 2015-2019 (US$ billion, AGR %)
  • 15.6 Biogen Inc.
    • 15.6.1 Company Overview
    • 15.6.2 Total Company Sales 2016 - 2019
    • 15.6.3 Products / Services
    • 15.6.4 Mergers & Acquisitions (M&A) Activity
  • 15.7 Teva Pharmaceuticals
    • 15.7.1 Company Overview
    • 15.7.2 Total Company Sales 2016 - 2019
    • 15.7.3 Products / Services
  • 15.8 Alexion Pharmaceuticals, Inc.
    • 15.8.1 Company Overview
    • 15.8.2 Total Company Sales 2016 - 2019
    • 15.8.3 Products / Services
  • 15.9 Sanofi S.A.
    • 15.9.1 Company Overview
    • 15.9.2 Total Company Sales 2016 - 2019
    • 15.9.3 Products / Services
  • 15.10 Abbive
    • 15.10.1 Company Overview
    • 15.10.2 Total Company Sales 2016 - 2019
    • 15.10.3 Products / Services
    • 15.10.4 Mergers & Acquisitions (M&A) Activity
  • 15.11 Bristol Myers Squibb
    • 15.11.1 Company Overview
    • 15.11.2 Total Company Sales 2016 - 2019
    • 15.11.3 Products / Services
  • 15.12 Takeda Pharmaceuticals
    • 15.12.1 Company Overview
    • 15.12.2 Total Company Sales 2017 - 2020
    • 15.12.3 Products / Services
  • 15.13 Roche
    • 15.13.1 Company Overview
    • 15.13.2 Total Company Sales 2016 - 2019
    • 15.13.3 Products / Services
  • 15.14 Johnson & Johnson Services, Inc.
    • 15.14.1 Company Overview
    • 15.14.2 Products / Services
    • 15.14.3 Financials, 2015-2019 (US$ billion, AGR %)
    • 15.14.4 Mergers & Acquisitions (M&A) Activity

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks
  • 16.2 Recommendations

List of Tables

  • Table 1 Global Rare Diseases Market Snapshot, 2021 & 2030 (US$ billion, CAGR %)
  • Table 2 Pfizer Rare Disease Pipeline
  • Table 3 Genzyme Corporation Rare Disease Pipeline
  • Table 4 Takeda Rare Disease Pipeline
  • Table 5 Key Factors Affecting the Bargaining Power of Buyer
  • Table 6 Key Factors Affecting the Bargaining Power of Suppliers
  • Table 7 Key Factors Affecting the Threat of Substitutes
  • Table 8 Key Factors Affecting the Threat of New Entrants
  • Table 9 Key Factors Affecting the Industry Rivalry
  • Table 10 Global Rare Diseases Market Forecast by Disease, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 11 Global Rare Diseases Market Forecast by Revlimid, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 12 Global Rare Diseases Market Forecast by MabThera/Rituxan, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 13 Global Rare Diseases Market Forecast by Opdivo, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 14 Global Rare Diseases Market Forecast by Imbruvica, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 15 Global Rare Diseases Market Forecast by Sprycel, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 16 Global Rare Diseases Market Forecast by Avonex, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 17 Global Rare Diseases Market Forecast by Tasigna, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 18 Global Rare Diseases Market Forecast by Copaxone, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 19 Global Rare Diseases Market Forecast by Rebif, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 20 Global Rare Diseases Market Forecast by Gleevec, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 21 Global Rare Diseases Market Forecast by Velcade, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 22 Global Rare Diseases Market Forecast by Others, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 23 Global Rare Diseases Market Forecast by Disease, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 24 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 25 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 26 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 27 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 28 Global Rare Diseases Market Forecast by Rare Oncology Diseases, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 29 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 30 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 31 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 32 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 33 Global Rare Diseases Market Forecast by Rare Metabolic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 34 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 35 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 36 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 37 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 38 Global Rare Diseases Market Forecast by Rare Neurologic Diseases , 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 39 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 40 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 41 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 42 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 43 Global Rare Diseases Market Forecast by Rare Hematology Diseases , 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 44 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 45 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 46 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 47 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 48 Global Rare Diseases Market Forecast by Rare Infectious Diseases , 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 49 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 50 Global Rare Diseases Market Forecast by Other Rare Diseases, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 51 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 52 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 53 Global Rare Diseases Market Forecast by Other Rare Diseases , 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 54 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 55 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 56 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 57 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 58 Global Rare Diseases Market Forecast by non-biologics, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 59 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 60 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 61 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 62 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 63 Global Rare Diseases Market Forecast by Biologics, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 64 Global Rare Diseases Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
  • Table 65 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 66 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 67 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 68 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 69 Global Rare Diseases Market Forecast by Adult, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 70 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 71 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 72 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 73 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 74 Global Rare Diseases Market Forecast by Pediatric, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 75 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 76 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 77 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 78 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 79 Global Rare Diseases Market Forecast by Specialty Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 80 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 81 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 82 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 83 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 84 Global Rare Diseases Market Forecast by Hospital Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 85 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 86 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 87 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 88 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 89 Global Rare Diseases Market Forecast by Retail Pharmacies, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 90 Global Rare Diseases Market Forecast by Region, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 91 Global Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 92 Global Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 93 Global Rare Diseases Market Forecast , 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 94 Global Rare Diseases Market Forecast , 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 95 U.S. clinical trial landscape for rare disease, 2021
  • Table 96 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 97 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 98 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 99 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 100 U.S. Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 101 Canada clinical trial landscape for rare diseases, 2021
  • Table 102 Canada Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 103 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 104 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 105 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 106 Canada Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 107 List of drugs used in treating rare diseases
  • Table 108 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 109 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 110 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 111 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 112 Germany Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 113 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 114 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 115 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 116 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 117 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 118 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 119 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 120 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 121 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 122 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 123 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 124 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 125 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 126 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 127 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 128 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 129 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 130 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 131 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 132 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 133 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 134 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 135 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 136 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 137 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 138 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 139 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 140 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 141 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 142 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 143 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 144 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 145 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 146 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 147 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 148 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 149 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 150 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 151 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 152 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 153 National initiatives to support rare diseases and access to orphan drugs
  • Table 154 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 155 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 156 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 157 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 158 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 159 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 160 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 161 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 162 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 163 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 164 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 165 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 166 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 167 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 168 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 169 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 170 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 171 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 172 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 173 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 174 National Laws on Rare Diseases in 6 Latin American Countries
  • Table 175 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 176 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 177 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 178 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 179 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 180 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 181 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 182 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 183 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 184 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 185 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 186 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 187 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 188 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 189 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 190 UAE Medicines with Fast Track Registration
  • Table 191 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 192 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 193 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 194 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 195 UAE Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 196 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 197 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 198 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 199 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 200 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 201 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Table 202 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "V" Shaped Recovery
  • Table 203 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "U" Shaped Recovery
  • Table 204 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "W" Shaped Recovery
  • Table 205 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, AGR%): "L" Shaped Recovery
  • Table 206 Pfizer Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 207 Pfizer Products / Services
  • Table 208 Pfizer Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 209 Novartis AG Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 210 Novartis AG Products / Services
  • Table 211 Novartis AG Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 212 Merck KGaA Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 213 Merck KGaA Products / Services
  • Table 214 Merck KGaA Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 215 F. Hoffmann-La Roche Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 216 F. Hoffmann-La Roche Ltd Products / Services
  • Table 217 F. Hoffmann-La Roche Ltd Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 218 Amgen Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 219 Amgen Inc.Products / Services
  • Table 220 Amgen Inc.Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 221 Amgen Inc. Company overview
  • Table 222 Amgen Inc. Products / Services
  • Table 223 Teva Pharmaceuticals Company overview
  • Table 224 Teva Pharmaceuticals Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 225 Teva Pharmaceuticals Products / Services
  • Table 226 Alexion Pharmaceuticals, Inc Company overview
  • Table 227 Alexion Pharmaceuticals, Inc Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 228 Alexion Pharmaceuticals, Inc Products / Services
  • Table 229 Sanofi S.A. Company overview
  • Table 230 Sanofi S.A. Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 231 Sanofi S.A. Products / Services
  • Table 232 Abbive Company overview
  • Table 233 Abbive Total Company Sales 2016 - 2019
  • Table 234 Abbive Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 235 Abbive Products / Services
  • Table 236 Bristol Myers Squibb Company overview
  • Table 237 Bristol Myers Squibb Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Table 238 Bristol Myers Squibb Products / Services
  • Table 239 Company overview
  • Table 240 Takeda Pharmaceuticals Total Company Sales, 2017 - 2020 (US$ million, AGR %)
  • Table 241 Takeda Pharmaceuticals Products / Services
  • Table 242 Roche Company overview
  • Table 243 Roche Total Company Sales, 2017 - 2020 (US$ million, AGR %)
  • Table 244 Roche Products / Services
  • Table 245 Johnson & Johnson Services, Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 246 Johnson & Johnson Services, Inc Products / Services
  • Table 247 Johnson & Johnson Services, Inc Total Company Sales 2015-2019 (US$ million, AGR %)

List of Figures

  • Figure 1 Global Rare Diseases Market: Market Segmentation
  • Figure 2 Global Rare Diseases Market: Market Trends
  • Figure 3 CDER's Annual Novel Drug Approvals: 2011 - 2020
  • Figure 4 Global Rare Disease Market: SWOT Analysis
  • Figure 5 Global Rare Disease Market: Porter's Five Forces Analysis
  • Figure 6 Global Rare Diseases Market Forecast by Drugs, 2021-2031 (US$ billion, AGR %)
  • Figure 7 Global Rare Diseases Market Share Forecast by Drugs, 2021, 2026, 2031 (%)
  • Figure 8 Global Rare Diseases Market for Revlimid Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 9 Global Rare Diseases Market for MabThera/Rituxan Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 10 Global Rare Diseases Market for Opdivo Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 11 Global Rare Diseases Market for Imbruvica Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 12 Global Rare Diseases Market for Sprycel Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 13 Global Rare Diseases Market for Avonex Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 14 Global Rare Diseases Market for Tasigna Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 15 Global Rare Diseases Market for Copaxone Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 16 Global Rare Diseases Market for Rebif Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 17 Global Rare Diseases Market for Gleevec Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 18 Global Rare Diseases Market for Velcade Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 19 Global Rare Diseases Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 20 Global Rare Diseases Market Forecast by Disease, 2021-2031 (US$ billion, AGR %)
  • Figure 21 Global Rare Diseases Market Share Forecast by Disease, 2021, 2026, 2031 (%)
  • Figure 22 Global Rare Diseases Market for Rare Oncology Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 23 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 24 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 25 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 26 Global Rare Diseases Market for Rare Oncology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 27 Global Rare Diseases Market for Rare Metabolic Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 28 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 29 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 30 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 31 Global Rare Diseases Market for Rare Metabolic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 32 Global Rare Diseases Market for Rare Neurologic Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 33 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 34 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 35 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 36 Global Rare Diseases Market for Rare Neurologic Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 37 Global Rare Diseases Market for Rare Hematology Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 38 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 39 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 40 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 41 Global Rare Diseases Market for Rare Hematology Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 42 Global Rare Diseases Market for Rare Infectious Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 43 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 44 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 45 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 46 Global Rare Diseases Market for Rare Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 47 Global Rare Diseases Market for Other Rare Diseases Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 48 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 49 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 50 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 51 Global Rare Diseases Market for Other Rare Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 52 Global Rare Diseases Market Forecast by Type, 2021-2031 (US$ billion, AGR %)
  • Figure 53 Global Rare Diseases Market Share Forecast by Type, 2021, 2026, 2031 (%)
  • Figure 54 Global Rare Diseases Market for Non Biologics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 55 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 56 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 57 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 58 Global Rare Diseases Market for Non Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 59 Global Rare Diseases Market for Biologics Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 60 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 61 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 62 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 63 Global Rare Diseases Market for Biologics Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 64 Global Rare Diseases Market Forecast by Age, 2021-2031 (US$ billion, AGR %)
  • Figure 65 Global Rare Diseases Market Share Forecast by Age, 2021, 2026, 2031 (%)
  • Figure 66 Global Rare Diseases Market for Adult Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 67 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 68 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 69 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 70 Global Rare Diseases Market for Adult Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 71 Global Rare Diseases Market for Pediatric Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 72 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 73 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 74 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 75 Global Rare Diseases Market for Pediatric Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 76 Global Rare Diseases Market Forecast by End Use, 2021-2031 (US$ billion, AGR %)
  • Figure 77 Global Rare Diseases Market Share Forecast by End Use, 2021, 2026, 2031 (%)
  • Figure 78 Global Rare Diseases Market for Specialty Pharmacies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 79 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 80 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 81 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 82 Global Rare Diseases Market for Specialty Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 83 Global Rare Diseases Market for Hospital Pharmacies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 84 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 85 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 86 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 87 Global Rare Diseases Market for Hospital Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 88 Global Rare Diseases Market for Retail Pharmacies Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
  • Figure 89 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 90 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 91 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 92 Global Rare Diseases Market for Retail Pharmacies Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 93 Global Rare Diseases Market Forecast by Region 2021-2031 (US$ billion)
  • Figure 94 Global Rare Diseases Market Share Forecast by Region 2021, 2026, 2031 (%)
  • Figure 95 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 96 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 97 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 98 Global Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 99 North America Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 100 North America Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 101 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 102 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 103 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 104 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 105 U.S. Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 106 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 107 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 108 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 109 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 110 Canada Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 111 Europe Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 112 Europe Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 113 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 114 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 115 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 116 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 117 Germany Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 118 UK Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 119 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 120 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 121 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 122 UK Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 123 France Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 124 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 125 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 126 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 127 France Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 128 Italy Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 129 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 130 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 131 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 132 Italy Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 133 Spain Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 134 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 135 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 136 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 137 Spain Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 138 Russia Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 139 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 140 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 141 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 142 Russia Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 143 Denmark Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 144 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 145 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 146 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 147 Denmark Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 148 Netherlands Rare Diseases Market Forecast by Country, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 149 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 150 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 151 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 152 Netherlands Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 153 ROEu Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 154 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 155 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 156 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 157 Rest of Europe Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 158 Asia Pacific Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 159 Asia Pacific Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 160 Japan Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 161 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 162 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 163 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 164 Japan Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 1 China Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 165 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 166 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 167 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 168 China Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 169 Disease-associated founder variations prevalent in India
  • Figure 170 India Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 171 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 172 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 173 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 174 India Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 175 RoAPAC Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 176 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 177 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 178 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 179 Rest of Asia Pacific Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 180 Latin America Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 181 Latin America Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 1 Brazil Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 182 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 183 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 184 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 185 Brazil Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 186 Mexico Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 187 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 188 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 189 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 190 Mexico Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 1 ROLATAM Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 191 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 192 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 193 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 194 Rest of Latin America Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 195 Orphan disease likely coverage across MENA regions based on current environment
  • Figure 196 Middle East and Africa Rare Diseases Market Forecast by Country 2021-2031 (US$ billion)
  • Figure 197 Middle East and Africa Rare Diseases Market Share Forecast by Country 2021, 2026, 2031 (%)
  • Figure 198 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR %)
  • Figure 199 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 200 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 201 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 202 UAE Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 203 South Africa Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 204 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 205 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 206 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 207 South Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 208 RoMEA Rare Diseases Market Forecast, 2021-2031 (US$bn, AGR%, CAGR%)
  • Figure 209 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "V" Shaped Recovery
  • Figure 210 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "U" Shaped Recovery
  • Figure 211 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "W" Shaped Recovery
  • Figure 212 Rest of Middle East and Africa Rare Diseases Market Forecast, 2021-2031 (US$ billion, AGR%): "L" Shaped Recovery
  • Figure 213 Pfizer Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Figure 214 Novartis AG Total Company Sales 2015-2018 (US$ million, AGR %)
  • Figure 215 Merck KGaA Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Figure 216 F. Hoffmann-La Roche Ltd Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Figure 217 Amgen Inc.Total Company Sales, 2015-2019 (US$ million, AGR %)
  • Figure 218 Amgen Inc.Total Company Sales 2016 - 2019
  • Figure 219 Teva Pharmaceuticals Total Company Sales 2016 - 2019
  • Figure 220 Alexion Pharmaceuticals, Inc Total Company Sales 2016 - 2019
  • Figure 221 Sanofi S.A. Total Company Sales 2016 - 2019
  • Figure 222 Bristol Myers Squibb Total Company Sales 2016 - 2019
  • Figure 223 Takeda Pharmaceuticals Total Company Sales 2017 - 2020
  • Figure 224 Roche Total Company Sales 2016 - 2019
  • Figure 225 Johnson & Johnson Services, Inc Total Company Sales (US$ million, AGR %)
  • Figure 226 Global Rare Diseases Market Forecast by Region 2021-2031 (US$ billion)

Companies Profiled in the Report:

  • AbbVie
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Roche
  • Sanofi S.A.
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals

List of Other Companies in the Global Rare Diseases Market:

  • 3billion
  • Aeglea BioTherapeutics
  • Agios Pharmaceuticals
  • AGTC (Applied Genetics Technology Corp)
  • Akcea Therapeutics
  • Alexion
  • Allievex
  • Amicus Therapeutics
  • Amryt Pharma
  • Apic Bio
  • Ascendis Pharma
  • Attune Pharmaceuticals
  • Azafaros
  • BioCryst Pharmaceuticals
  • BioMarin Pharmaceuticals
  • BioXcel Therapeutics
  • CureVac
  • Emmaus
  • Harmony Biosciences
  • Levo Therapeutics

List of Organizations:

  • APEC LSIF Rare Disease Network
  • Asia Pacific Alliance of Rare Disease Organisations (APARDO)
  • ERA-Net for Research Programmes on Rare Diseases (E-Rare)
  • European Organisation for Rare Diseases (EURORDIS)
  • European Platform for Rare Disease Registries (EPIRARE)
  • European Union Committee of Experts on Rare Diseases (EUCERD)
  • Global Commission to End the Diagnostic Odyssey for Children
  • INNOVCare
  • International Coalition of Organizations Supporting Endocrine Patients (ICOSEP)
  • International Conference on Rare Diseases & Orphan Drugs (ICORD)
  • International Rare Diseases Research Consortium (IRDiRC)
  • National Organization for Rare Disorders
  • NGO Committee for Rare Diseases
  • Organization For Rare Diseases India
  • Orphanet
  • Rare Disease Day
  • Rare Diseases International (RDI)
  • RareConnect
  • RD-Connect
  • The World Association of Cured Rare Diseases (WACRD)
  • The World Association of Orphan Diseases (WAO(R)D)